S&P 500   3,109.09 (+0.18%)
DOW   27,859.98 (+0.34%)
QQQ   201.66 (-0.02%)
BABA   186.58 (+0.92%)
T   37.79 (+0.51%)
F   8.89 (+2.07%)
BAC   33.13 (+0.88%)
S&P 500   3,109.09 (+0.18%)
DOW   27,859.98 (+0.34%)
QQQ   201.66 (-0.02%)
BABA   186.58 (+0.92%)
T   37.79 (+0.51%)
F   8.89 (+2.07%)
BAC   33.13 (+0.88%)
S&P 500   3,109.09 (+0.18%)
DOW   27,859.98 (+0.34%)
QQQ   201.66 (-0.02%)
BABA   186.58 (+0.92%)
T   37.79 (+0.51%)
F   8.89 (+2.07%)
BAC   33.13 (+0.88%)
S&P 500   3,109.09 (+0.18%)
DOW   27,859.98 (+0.34%)
QQQ   201.66 (-0.02%)
BABA   186.58 (+0.92%)
T   37.79 (+0.51%)
F   8.89 (+2.07%)
BAC   33.13 (+0.88%)
Log in

Corbus Pharmaceuticals Stock Price, Forecast & Analysis (NASDAQ:CRBP)

$4.63
-0.14 (-2.94 %)
(As of 11/22/2019 03:44 PM ET)
Today's Range
$4.51
Now: $4.63
$4.79
50-Day Range
$4.29
MA: $4.86
$5.43
52-Week Range
$4.18
Now: $4.63
$9.11
Volume62,663 shs
Average Volume821,617 shs
Market Capitalization$299.42 million
P/E RatioN/A
Dividend YieldN/A
Beta1.87
Corbus Pharmaceuticals Holdings, Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its lead product candidate is lenabasum, a synthetic oral endocannabinoid drug that is in Phase 3 clinical trial for the treatment of systemic sclerosis and dermatomyositis, and in Phase 2 clinical trial to treat systemic lupus erythematosus and cystic fibrosis. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CRBP
CUSIPN/A
Phone617-963-0100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.82 million
Book Value$0.46 per share

Profitability

Net Income$-55,670,000.00
Net Margins-175.16%

Miscellaneous

Employees77
Market Cap$299.42 million
Next Earnings Date3/10/2020 (Estimated)
OptionableOptionable

Receive CRBP News and Ratings via Email

Sign-up to receive the latest news and ratings for CRBP and its competitors with MarketBeat's FREE daily newsletter.


Corbus Pharmaceuticals (NASDAQ:CRBP) Frequently Asked Questions

What is Corbus Pharmaceuticals' stock symbol?

Corbus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRBP."

How were Corbus Pharmaceuticals' earnings last quarter?

Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) announced its quarterly earnings data on Thursday, November, 7th. The biopharmaceutical company reported ($0.32) earnings per share for the quarter, beating analysts' consensus estimates of ($0.36) by $0.04. The biopharmaceutical company had revenue of $2.59 million for the quarter, compared to analyst estimates of $1.73 million. Corbus Pharmaceuticals had a negative net margin of 175.16% and a negative return on equity of 169.38%. View Corbus Pharmaceuticals' Earnings History.

When is Corbus Pharmaceuticals' next earnings date?

Corbus Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, March 10th 2020. View Earnings Estimates for Corbus Pharmaceuticals.

What price target have analysts set for CRBP?

6 analysts have issued 12 month price objectives for Corbus Pharmaceuticals' shares. Their forecasts range from $18.00 to $38.00. On average, they expect Corbus Pharmaceuticals' share price to reach $26.50 in the next twelve months. This suggests a possible upside of 472.4% from the stock's current price. View Analyst Price Targets for Corbus Pharmaceuticals.

What is the consensus analysts' recommendation for Corbus Pharmaceuticals?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corbus Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Corbus Pharmaceuticals.

What are Wall Street analysts saying about Corbus Pharmaceuticals stock?

Here are some recent quotes from research analysts about Corbus Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. " (11/8/2019)
  • 2. HC Wainwright analysts commented, "Valuation and risks to our investment thesis. Our price target of $24/share is based on an equally weighted composite of: (a) $23.83/share, as a 35x multiple of taxed and diluted $5.60 discounted back to FY19 at 18% (in line with the expected P/E multiple and discount rate of an early development stage biotechnology company); and (b) an NPV of $24/share (discounted cash flow analysis using a 15.5% discount rate and 2% growth rate, in line with the expected discount and growth parameters of an early development-stage biotechnology company)." (5/10/2019)

Has Corbus Pharmaceuticals been receiving favorable news coverage?

News headlines about CRBP stock have been trending somewhat negative this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Corbus Pharmaceuticals earned a news sentiment score of -1.0 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Corbus Pharmaceuticals.

Who are some of Corbus Pharmaceuticals' key competitors?

What other stocks do shareholders of Corbus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Corbus Pharmaceuticals investors own include Visa (V), HP (HPQ), Fortive (FTV), Lowe's Companies (LOW), Viveve Medical (VIVE), Exelixis (EXEL), Western Digital (WDC), Canopy Growth (CGC), Cronos Group (CRON) and Cara Therapeutics (CARA).

Who are Corbus Pharmaceuticals' key executives?

Corbus Pharmaceuticals' management team includes the folowing people:
  • Dr. Yuval Cohen, CEO & Director (Age 44)
  • Mr. Sean F. Moran CPA, M.B.A., CPA, MBA, Chief Financial Officer (Age 61)
  • Dr. Mark A. Tepper, Co-Founder & Consultant (Age 62)
  • Dr. Barbara White, Chief Medical Officer (Age 69)
  • Ted Jenkins, Sr. Director of Investor Relations & Communications

Who are Corbus Pharmaceuticals' major shareholders?

Corbus Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Russell Investments Group Ltd. (0.34%), Alps Advisors Inc. (0.20%), AE Wealth Management LLC (0.16%), D.A. Davidson & CO. (0.08%), Exane Derivatives (0.05%) and California Public Employees Retirement System (0.04%). Company insiders that own Corbus Pharmaceuticals stock include Barbara White, Craig Stuart Millian, David P Hochman, John Kenneth Jenkins, Robert Paul Discordia, Sean F Moran and Yuval Cohen. View Institutional Ownership Trends for Corbus Pharmaceuticals.

Which major investors are selling Corbus Pharmaceuticals stock?

CRBP stock was sold by a variety of institutional investors in the last quarter, including Alps Advisors Inc., Exane Derivatives, AE Wealth Management LLC and Aries Wealth Management. View Insider Buying and Selling for Corbus Pharmaceuticals.

Which major investors are buying Corbus Pharmaceuticals stock?

CRBP stock was bought by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., California Public Employees Retirement System and D.A. Davidson & CO.. Company insiders that have bought Corbus Pharmaceuticals stock in the last two years include Barbara White, Craig Stuart Millian, David P Hochman, John Kenneth Jenkins, Robert Paul Discordia, Sean F Moran and Yuval Cohen. View Insider Buying and Selling for Corbus Pharmaceuticals.

How do I buy shares of Corbus Pharmaceuticals?

Shares of CRBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Corbus Pharmaceuticals' stock price today?

One share of CRBP stock can currently be purchased for approximately $4.63.

How big of a company is Corbus Pharmaceuticals?

Corbus Pharmaceuticals has a market capitalization of $299.42 million and generates $4.82 million in revenue each year. The biopharmaceutical company earns $-55,670,000.00 in net income (profit) each year or ($0.98) on an earnings per share basis. Corbus Pharmaceuticals employs 77 workers across the globe.View Additional Information About Corbus Pharmaceuticals.

What is Corbus Pharmaceuticals' official website?

The official website for Corbus Pharmaceuticals is http://www.corbuspharma.com/.

How can I contact Corbus Pharmaceuticals?

Corbus Pharmaceuticals' mailing address is 500 River Ridge Drive, Norwood MA, 02062. The biopharmaceutical company can be reached via phone at 617-963-0100 or via email at [email protected]


MarketBeat Community Rating for Corbus Pharmaceuticals (NASDAQ CRBP)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  332 (Vote Outperform)
Underperform Votes:  214 (Vote Underperform)
Total Votes:  546
MarketBeat's community ratings are surveys of what our community members think about Corbus Pharmaceuticals and other stocks. Vote "Outperform" if you believe CRBP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRBP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/22/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel